R&D Investment to Create High-Value-Added Products and New Businesses

「本研究で確立した「不均一系有機触媒×連続フロー合成」は、医薬品原薬の持続可能な製造を実現する基盤技術となることが期待されます。今後も、触媒のさらなる長寿命化やスケールアップ検討を進めるとともに、他の医薬品原薬や農薬原体など幅広い化学品への応用を推進していきます。」

「For advanced communications CCL materials, the company was an early market entrant with 1,2-SBS (styrene-butadiene-styrene), developed using its proprietary precision polymerization technology, achieving differentiation in the market.」

「The Group's R&D expenses for the interim consolidated accounting period were ¥2,946 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」

「The Group's R&D expenses for the interim consolidated accounting period were ¥2,638 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」

「Specifically, the company will strengthen and expand existing businesses in the priority fields of agriculture, healthcare, the environment and ICT, while establishing food, medical care and advanced materials as the 3 target domains for new businesses and developing materials and active ingredients that contribute to society. It will also strengthen agrochemical creation technology, bioresource utilization technology and functional materials creation technology, based on the use of its own resources and technologies, as platform technologies, and seek to create new value by combining technologies from inside and outside the company. Total R&D expenses were ¥6,422 million, equivalent to 4.2% of consolidated sales, with a Group-wide R&D workforce of 337, or 14.0% of total employees.」

「The Group's R&D expenses for the cumulative third quarter were ¥4,056 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」

「The Group's R&D expenses for the cumulative second quarter were ¥2,707 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」

「The Group's R&D expenses for the cumulative first quarter were ¥1,421 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」

「The Group's R&D expenses for the cumulative third quarter were ¥4,023 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」

「The Group's R&D expenses for the cumulative second quarter were ¥2,783 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」

「The Group's R&D expenses for the cumulative first quarter were ¥1,448 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」

「Total R&D expenses were ¥5,844 million, equivalent to 3.8% of consolidated sales, with a Group-wide R&D workforce of 341, or 12.2% of total employees. In January 2022, the company launched Liquid 1,2-SBS (styrene-butadiene-styrene), a new functional polymer developed using its precision polymerization technology.」

「The Group's R&D expenses for the cumulative third quarter were ¥3,930 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」

「The Group's R&D expenses for the cumulative second quarter were ¥2,531 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」

「The Group's R&D expenses for the cumulative first quarter were ¥1,276 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」

「Total R&D expenses were ¥5,791 million, equivalent to 4.2% of consolidated sales, with a Group-wide R&D workforce of 349, or 12.6% of total employees.」

「The Group's R&D expenses for the cumulative third quarter were ¥3,854 million. The company reports the following progress during the cumulative third quarter: [Agricultural Chemicals Business] Global development of the fungicide Ipflufenquin (NF-180), which is effective against a broad range of diseases, is progressing smoothly, and domestic registration was approved on 14 July 2020. Registration in overseas countries, including those in Europe and North America, is planned.」

「The Group's R&D expenses for the cumulative second quarter were ¥2,493 million. Global development of the fungicide Ipflufenquin (NF-180), which is effective against a broad range of diseases, is progressing smoothly, and domestic registration was approved on 14 July 2020. Registration in overseas countries, including those in Europe and North America, is planned.」

「The Group's R&D expenses for the cumulative first quarter were ¥1,232 million. The company reports the following progress during the cumulative first quarter: [Agricultural Chemicals Business] Global development of the fungicide Ipflufenquin (NF-180), which is effective against a broad range of diseases, is progressing smoothly, and domestic registration was approved on 14 July 2020. Registration in overseas countries, including those in Europe and North America, is planned.」

「Total R&D expenses were ¥6,127 million, equivalent to 4.2% of consolidated sales, with a Group-wide R&D workforce of 325, or 11.8% of total employees.」

「The Group's R&D expenses for the cumulative third quarter were ¥4,456 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」

「The Group's R&D expenses for the cumulative second quarter were ¥2,947 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」

「In the cumulative first quarter, the company began selling new products in the Chemicals Business and saw an increase in plant construction work in the Construction Business. However, due to higher raw material prices and increased R&D and contract testing expenses, sales were ¥33,083 million, up 2.3% year on year, and operating income was ¥982 million, down 40.6% year on year.」

「Total R&D expenses were ¥6,241 million, equivalent to 4.3% of consolidated sales, with a Group-wide R&D workforce of 330, or 12.1% of total employees.」

「The Group's R&D expenses for the cumulative third quarter were ¥4,462 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」

「The Group's R&D expenses for the cumulative second quarter were ¥2,683 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」

「The Group's R&D expenses for the cumulative first quarter were ¥1,319 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」

「Total R&D expenses were ¥7,250 million, equivalent to 5.1% of consolidated sales, with a Group-wide R&D workforce of 338, or 12.6% of total employees. Among the new agrochemicals developed in-house, the fungicide Picarbutrazox (NF-171), which is highly effective against downy mildew and Pythium disease, received approval for turf registration in January 2017, followed by approval for registration for use in food crops in July 2017, and was successfully launched during FY2017.」

「The Group's R&D expenses for the cumulative third quarter were ¥4,983 million. The company reports the following progress during the cumulative third quarter: [Agricultural Chemicals Business] Registration of 3 fungicide formulations, including the new active ingredient fungicide Picarbutrazox (NF-171), which had been under development, for use in food crops was approved in July 2017.」

「The Group's R&D expenses for the cumulative first quarter were ¥1,479 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」

「To advance the development of high-value-added products based on distinctive proprietary technologies, the group conducts R&D under the key themes of "integration of knowledge," "integration of technologies" and "globalization." This includes research into various chemicals using functional materials and precision synthesis technologies in its chemicals business, as well as research aimed at developing new agrochemicals in its agricultural chemicals business. The group is also working to further strengthen and expand its existing products in preparation for expected changes in the business environment, vigorously promoting the development of new products in areas surrounding its existing businesses and in priority fields. In addition, it aims to strengthen the technological capabilities of the group as a whole through technological cooperation with affiliated companies, enter new technology fields and create new businesses through the active use of technologies held in-house. Total R&D expenses were ¥6,495 million, equivalent to 5.0% of consolidated net sales, with 368 employees, or 13.7% of total employees, engaged in R&D across the group.」

「The amount spent on R&D activities across the group during the nine months ended the third quarter of the current fiscal year was ¥4,204 million. There were no material changes in the status of the group's R&D activities during the nine months ended the third quarter of the current fiscal year.」

「The amount spent on R&D activities across the group during the six months ended the second quarter of the current fiscal year was ¥2,754 million. There were no material changes in the status of the group's R&D activities during the six months ended the second quarter of the current fiscal year.」

「The amount spent on R&D activities across the group during the first quarter of the current fiscal year was ¥1,379 million. There were no material changes in the status of the group's R&D activities during the first quarter of the current fiscal year.」

「Based on its basic policy of developing high-value-added products using distinctive proprietary technologies, the group conducts R&D aimed at developing various organic chemicals using functional materials and precision organic synthesis technologies in its chemicals business, as well as new agrochemicals in its agricultural chemicals business. Total R&D expenses were ¥6,670 million, equivalent to 4.7% of consolidated net sales, with 382 employees, or 14.3% of total employees, engaged in R&D across the group.」